Reducing residual cardiovascular risk with novel therapies

Curr Opin Lipidol. 2020 Apr;31(2):108-110. doi: 10.1097/MOL.0000000000000672.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anticholesteremic Agents / therapeutic use
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / etiology
  • Heart Disease Risk Factors
  • Humans
  • Hypolipidemic Agents / therapeutic use

Substances

  • Anticholesteremic Agents
  • Hypolipidemic Agents